CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...
Phase 3
Philadelphia, Pennsylvania, United States and 125 other locations
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...
Phase 3
Philadelphia, Pennsylvania, United States and 164 other locations
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children ...
Phase 1
Philadelphia, Pennsylvania, United States and 23 other locations
The purpose of the phase 1 portion (dose escalation) of the study will be to establish an optimally safe and biologically active recommended phase 2...
Phase 1, Phase 2
Philadelphia, Pennsylvania, United States and 24 other locations
People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML hav...
Phase 1, Phase 2
Philadelphia, Pennsylvania, United States and 18 other locations
This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular geneti...
Phase 1, Phase 2
Philadelphia, Pennsylvania, United States and 3 other locations
or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...
Phase 1, Phase 2
Wilmington, Delaware, United States and 27 other locations
\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...
Phase 3
Philadelphia, Pennsylvania, United States and 73 other locations
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...
Phase 3
Philadelphia, Pennsylvania, United States of America and 160 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...
Phase 2
Philadelphia, Pennsylvania, United States and 43 other locations
Clinical trials
Research sites
Resources
Legal